AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03946657
Drug: Intravenous anesthetic
RxNorm normalized name: Intravenous anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
Trial: NCT01324596
Drug: Intravenous
RxNorm normalized name: INTRAVENOUS SETS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoimmunotheraphy
Trial: NCT03705832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT04241601
Drug: Interleukin-2 [IL-2]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
Trial: NCT01880528
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00750802
Drug: AZD6280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg Capsule, oral, single-dose
Trial: NCT00750802
Drug: AZD6280
DrugBank: AZD-6280 (DB12210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg Capsule, oral, single-dose
Trial: NCT00750802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00918983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intraprostatic injection of placebo
Trial: NCT01122160
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with berries (blackberries + strawberries)
Trial: NCT02721173
Drug: Adapalene 0.1% gel plus clindamycin 1% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
Trial: NCT06081699
Drug: TNP-2198 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo for TNP-2198 active drug
Trial: NCT00038766
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV
Trial: NCT00904046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken orally once a day for 6 months.
Trial: NCT04058366
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Trial: NCT01974687
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to uprifosbuvir capsule administered by mouth.
Trial: NCT00972985
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, single acute dose
Trial: NCT04124822
Drug: Piroxicam 20 mg
RxNorm normalized name: piroxicam 20 MG
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
Trial: NCT04124822
Drug: prednisolone 20 mg
RxNorm normalized name: prednisolone 20 MG
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
Trial: NCT00626678
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
Trial: NCT00626678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
Trial: NCT01497600
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
Trial: NCT00545051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po monthly for 12 months
Trial: NCT00545051
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 12 months
Trial: NCT03094897
Drug: 18F-Al-NOTA-MATBBN PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
Trial: NCT00480376
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02590133
Drug: Fluorouracil (5-Fu)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
Trial: NCT01039090
Drug: Usual dopaminergic per os treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific change in the dopaminergic per os treatment
Trial: NCT02187211
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02187211
Drug: Placebo (for Minocycline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03568331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT00079989
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04342793
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04342793
Drug: ALS-L1023 1,200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALS-L1023
Trial: NCT04342793
Drug: ALS-L1023 1,800mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALS-L1023
Trial: NCT02183051
Drug: Meloxicam 7.5 mg
RxNorm normalized name: meloxicam 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183051
Drug: Meloxicam 1.875 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183051
Drug: Ibuprofen 200 mg
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02183051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183051
Drug: Meloxicam 15 mg
RxNorm normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02183051
Drug: Ibuprofen 400 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00407576
Drug: [11C]MeS-IMPY
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01944371
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
Trial: NCT00069108
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed, in 2 week cycles
Trial: NCT00069108
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As prescribed, in 2 week cycles
Trial: NCT00069108
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 po bid on days 1-15 of each 3 week cycle
Trial: NCT04617561
Drug: Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
Trial: NCT01093261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days.
Trial: NCT00580645
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00682890
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo birth control pill daily
Trial: NCT00069719
Drug: Glaucoma therapy
RxNorm normalized name: Sympathomimetics in glaucoma therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00414414
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04259515
Drug: Del Nido
RxNorm normalized name: Del Nido Cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Del Nido cardioplegic solution administered in a single dose at 15-20mg/Kg with a maximum dose of 1L of solution, administered antegrade or retrograde. In those patients in wich the crossclamping time exceed 90 to 120 minutes a manteinance dose of 500ml will be administered.
Trial: NCT04259515
Drug: Buckberg
RxNorm normalized name: ISOPROPYL ALCOHOL 80 mL in 100 mL TOPICAL GEL [Buckler Signature Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buckberg cardioplegical solution administered antegrade and/or retrograde at 1-2ml/Kg for cardiac arrest induction. Arrest manteinance with antegrade and/or retrograde administration at 1-2ml/Kg every 15 to 20 minutes. Reperfusion dose with antegrade or retrograde administration at 15-20 ml/Kg before removing the aortic crossclamp.
Trial: NCT02212210
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00326404
Drug: Desogestrel-Ethinyl Estradiol 21 tablets
RxNorm normalized name: desogestrel / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
Trial: NCT00326404
Drug: Desogestrel-Ethinyl Estradiol 28 tablets
RxNorm normalized name: desogestrel / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
Trial: NCT04602221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, Film-coated tablet
Trial: NCT03118986
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
Trial: NCT00819390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally, once daily for 12 weeks.
Trial: NCT02187627
Drug: [11C]RO6924963
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of \[11C\]RO6924963 injected will be \</=10 micrograms (mcg), injection volume \</=20 milliliters (mL). Target injected activity for \[11C\]RO6924963 will be 370-740 megabecquerel (MBq) \[10-20 millicurie (mCi)\].
Trial: NCT03182218
Drug: Direct oral anticoagulant
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
Trial: NCT01191268
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01222026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1000mg Calcium 800 IE Vitamin-D
Trial: NCT02058654
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine powder (5 g)
Trial: NCT02058654
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bulking agent powder (5 g)
Trial: NCT04641871
Drug: Sym021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Trial: NCT04641871
Drug: Sym022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Trial: NCT04641871
Drug: Sym023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.
Trial: NCT01386073
Drug: FreshKote
RxNorm normalized name: FreshKote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times a day for three months
Trial: NCT00986973
Drug: Sapropterin
RxNorm normalized name: Sapropterin
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
Trial: NCT01536418
Drug: GSK1605786A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 milligrams twice daily, orally adminstered for 12 weeks
Trial: NCT03390647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6130-matched placebo
Trial: NCT00577837
Drug: experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, 200 mg risedronate monthly for 6 months
Trial: NCT04486326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00888004
Drug: AFQ056
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00888004
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02434497
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
Trial: NCT00619203
Drug: Glycerol and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7
Trial: NCT00619203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebos, one po, one suppository
Trial: NCT00619203
Drug: Paracetamol and glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses
Trial: NCT01535560
Drug: AL-60371, 0.3% otic suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational otic suspension intended for the treatment of acute otitis externa
Trial: NCT03432221
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
Trial: NCT01688830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01736865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01304433
Drug: Venofundin 6% / Tetraspan 6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venofundin 6% / Tetraspan 6%
Trial: NCT01957449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months.
Trial: NCT00505284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, once daily, for 15 weeks (taken orally).
Trial: NCT00505284
Drug: E2007 (2 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel, 2 mg once daily, for 15 weeks (taken orally).
Trial: NCT00505284
Drug: E2007 (4 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
Trial: NCT00505284
Drug: E2007 (6 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
Trial: NCT00505284
Drug: E2007 (8 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
Trial: NCT02515435
Drug: apatinib single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
Trial: NCT02872246
Drug: BAY 987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Trial: NCT00252785
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01981395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
Trial: NCT00002570
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
Trial: NCT00002570
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/m2 IV - number of cycles is determined by patient and physician
Trial: NCT02403674
Drug: ATRIPLA™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One ATRIPLA™ tablet taken q.d. by mouth
Trial: NCT02403674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
Trial: NCT00126204
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02297503
Drug: Azzalure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glabellar lines
Trial: NCT00353054
Drug: Caltrate® 600 + D
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025103
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025103
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02463110
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02463110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03930186
Drug: Topical Therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.
Trial: NCT01418092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT00021398
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00021398
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02895035
Drug: Phenylephrine-ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
Trial: NCT02895035
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
Trial: NCT03154086
Drug: GSK3352589
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
Trial: NCT03154086
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It will be available across all strengths to match active drug in the form of tablet for oral administration.